You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 07/23/2014

Company Name Symbol %Change
BIOGEN IDEC BIIB
11.17%
RPC INC RES
8.35%
MILLER ENERG MILL
7.82%
SEI INVESTME SEIC
6.14%
HELIX ENERGY HLX
4.68%
Sanofi-Aventis Crosses Below its 10-day MA (SNY)

Print Share

Dec 28, 2012 (Moving average crossovers via COMTEX) -- Today, shares of Sanofi-Aventis (NYSE:SNY) have fallen below their 10-day MA of $47.23 on a volume of 231K shares. This may provide swing traders with an opportunity for a short position, as such a crossover often suggests lower prices in the near term.There is potential upside of 16.3% for shares of Sanofi-Aventis based on a current price of $46.88 and an average consensus analyst price target of $54.53. Sanofi-Aventis shares have support at the 50-day moving average (MA) of $44.96 and additional support at the 200-day MA of $40.32.

In the past 52 weeks, Sanofi-Aventis share prices have been bracketed by a low of $33.03 and a high of $47.97 and are now at $46.88, 42% above that low price. The 200-day and 50-day moving averages have moved 0.34% higher and 0.59% higher over the past week, respectively.

Sanofi-Aventis is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.

---------------------------------------------------------------------------------------------

Financial News Network Online (FNNO) is a leading provider of digital financial news content for distribution on the web. You can count on FNNO to bring you the latest market news, earnings reports, analyst comments, economic data reports and more. Visit http://www.fnno.com today.

Copyright, Comtex News Network, Inc. 2012

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.